Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Holding REGN?
Track your performance easily
REGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$728.68 - $1,211.20
Previous Close$731.3
Volume696.99K
Average Volume (3M)799.78K
Market Cap
$80.36B
Enterprise Value$73.27B
Total Cash (Recent Filing)$9.80B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)18.1
Beta0.74
Next Earnings
Jan 31, 2025EPS Estimate
$11.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)40.41
Shares Outstanding109,889,531
10 Day Avg. Volume858,121
30 Day Avg. Volume799,779
Standard Deviation0.09
R-Squared0.00232
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.74
Price to Sales (P/S)5.80
Price to Cash Flow (P/CF)15.60
P/FCF Ratio19.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.29
Enterprise Value/Gross Profit6.48
Enterprise Value/Ebitda13.32
Forecast
1Y Price Target
$1,098.62Price Target Upside50.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
PremiumMarket News
QQQ ETF Update, 12/23/2024 
PremiumMarket News
SPY ETF Update, 12/19/2024 
PremiumMarket News
QQQ ETF Update, 12/18/2024 
PremiumMarket News
VOO ETF Update, 12/17/2024 
PremiumMarket News
SPY ETF Update, 12/16/2024 PremiumMarket News
VOO ETF Update, 12/13/2024 Bulls Say, Bears Say
Bulls Say
Legal And Market ProtectionThe Federal Circuit is likely to uphold the preliminary injunctions against biosimilar competitors to Regeneron's Eylea.
Product Launch And Market PenetrationDupixent is expected to continue outperforming with its upcoming launch in Chronic obstructive pulmonary disease and continued dominance in Atopic dermatitis.
Stock ValuationThe stock is considered to be factoring in an overly bearish scenario for Eylea, implying potential undervaluation at current levels.
Bears Say
Investor ConcernsDespite a top- and bottom-line beat, today's Eylea HD miss and commentary on the evolving competitive landscape left investors questioning the path for Regeneron's ophthalmology business into 2025.
Market CompetitionThere are ongoing appeals from biosimilar competitors that could impact the market exclusivity of Regeneron's Eylea.
Sales PerformanceEylea HD's launch has underperformed compared to the competitor Vabysmo's matched-quarter revenues.
---
Ownership Overview
1.95% Insiders
34.02% Mutual Funds
19.66% Other Institutional Investors
20.02% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $728.68 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jan 31, 2025 which is in 39 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Oct 31, 2024. The company reported $12.46 earnings per share for the quarter, beating the consensus estimate of $11.695 by $0.765.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $11.27.
How many shares outstanding does Regeneron have?
Regeneron has 108,072,390 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.46 in its last earnings report, beating expectations of $11.695. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,098.62 (50.23% Upside)
$1,098.62 (50.23% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 56.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.52%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
16.41%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
REGN Company Deck
---
REGN Earnings Call
Q3 2024
0:00 / 0:00
---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$1,098.62
▲(50.23% Upside)
Technical Analysis
Best Analysts Covering REGN
1 Year
1 Year Success Rate
30/42 ratings generated profit
1 Year Average Return
+20.04%
reiterated a buy rating 13 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +20.04% per trade.
---